POLD1 and prostate adenocarcinoma: Moreover, POLD1 mRNA level was significantly associated with the DFI of patients with PRAD (HR: 4.73, 95% CI: 2.14–10.41, P < 0.001), SARC (HR: 1.61, 95% CI: 1.12–2.32, P = 0.011), and HCC (HR: 1.29, 95% CI: 1.06–1.58, P = 0.011) (Supplementary Figure S3B).